Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy

Recruiting now · Not applicable

Conditions studied: Lung Cancer, Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis, Non-Small-Cell Lung Cancer (NSCLC)

In brief

The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.

Key facts

Study ID

NCT06688422

Run by

The Cooper Health System

People needed

100

Starts

2024-12-01

Expected to finish

2026-12-01

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of advanced non-small-cell lung cancer
• Performance status (ECOG 0-1)
• Eligible for concurrent chemotherapy and radiation
• 18 years or older

You may not qualify if…

• Previous lung or thoracic surgery
• Enrollment in another pulmonary intervention trial
• Home oxygen usage prior to enrolment
• Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging
• Presence of active respiratory tract infection
• Uncontrolled nausea and vomiting
• Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy
• Inability or unwillingness of individual to give written informed consent

Where it is running

• MD Anderson Cancer Center at Cooper — Camden, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.